In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCB Pharma: Making Up for Lost Time

Executive Summary

Patent expiries across Europe of blockbuster allergy drug Zyrtec have hit UCB Pharma hard: the drug accounts for half of the mid-sized Belgian firm's revenues. Thus far, follow-on Xyzal has done poorly, prompting critics to accuse the group of complacency and lack of planning. But UCB has woken up. With some new senior pharma executives on board, it is determined to defend Xyzal-and its entire franchise-with strong clinical trial data; data which it hopes will also help convince governments, keen to de-reimburse antihistamines altogether, that allergy is a serious disease. Yet even if successful, this won't be enough to fill the Zyrtec gap. UCB needs to continue to push its promising anti-epileptic Keppra, and to cut its teeth in the in-licensing game.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts